# Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

> **NCT00237250** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 171 (actual)

## Conditions studied

- Prediabetic State

## Interventions

- **DRUG:** vildagliptin

## Key facts

- **NCT ID:** NCT00237250
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237250, "Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00237250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*